CN103371349A - Orally taken composition - Google Patents
Orally taken composition Download PDFInfo
- Publication number
- CN103371349A CN103371349A CN2013101470264A CN201310147026A CN103371349A CN 103371349 A CN103371349 A CN 103371349A CN 2013101470264 A CN2013101470264 A CN 2013101470264A CN 201310147026 A CN201310147026 A CN 201310147026A CN 103371349 A CN103371349 A CN 103371349A
- Authority
- CN
- China
- Prior art keywords
- acid
- vinegar
- oral compositions
- chondroitin sulfate
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Seasonings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an orally taken composition and a method of reducing the acidity of vinegar in the orally taken composition, wherein the acidity of vinegar in sour agents and vinegar is reduced. The orally taken composition comprises (A) at least one selected from chondroitin, chondroitin sulfate and salts thereof; and (B) at least one selected from sour agents and vinegar, wherein the weight-average molecular weight of the component (A) is 1000-15000 Da, 1500-15000 Da preferably, and 2000-15000 Da more preferably.
Description
Technical field
The present invention relates to interior oral compositions.More specifically, the interior oral compositions that the sour that relates to the vinegar in acid flavoring and the vinegar has reduced.
Background technology
Tart flavour food, medicine and quasi drug etc. can orally ingestible or the oral cavity in the goods that utilize, with saline taste, bitter taste, sweet taste etc., be the important element during the sense of taste forms, sometimes give by in said products, adding acid etc.
Yet, acid and vinegar have pungent taste, aftertaste (below, be called " sour of vinegar (
) "), when acid was made an addition to interior oral compositions, the sour of this vinegar became problem.
For example, such as in the patent documentation 1～3 record, in order to suppress the sour of tart flavour, vinegar, add the method for the sweeteners such as reduction malt sugar (the water Yee of It unit) or Sucralose in the oriented food etc.But, owing to be the sour that suppresses tart flavour, vinegar by the taste of giving other, thereby might destroy the balance of the taste of food etc., in addition, excessively with the sweet taste of sweetener, the aftertaste variation can not be satisfactory.
The prior art document
Patent documentation
Patent documentation 1: TOHKEMY 2004-89119 communique
Patent documentation 2: Japanese kokai publication hei 10-243776 communique
Patent documentation 3: Japanese kokai publication hei 10-215793 communique.
Summary of the invention
The technical problem that invention will solve
The method that problem of the present invention is to provide the interior oral compositions that the sour of the vinegar in acid flavoring and the vinegar reduced and the sour that makes the vinegar of interior oral compositions to reduce.
The means that are used for the technical solution problem
The inventor etc. have carried out repeatedly research, found that: by in acid flavoring or vinegar, cooperate have specific mean molecule quantity, be selected from least a in chondroitin, chondroitin sulfate and their salt, the composition that the sour that can obtain the vinegar in acid flavoring or the vinegar has reduced, thus the present invention finished.
That is, the present invention relates to:
(1) interior oral compositions, it contains (A) and is selected from least a in chondroitin, chondroitin sulfate and their salt and (B) is selected from least a in acid flavoring and the vinegar, and (A) weight average molecular weight of composition is 1000～15000Da; And
(2) method that the sour of the vinegar of interior oral compositions is reduced, it is characterized in that, in interior oral compositions, contain (B) and be selected from least a in acid flavoring and the vinegar, also contain simultaneously (A) and be selected from least a in chondroitin, chondroitin sulfate and their salt.
The invention effect
Even interior oral compositions of the present invention when containing acid flavoring or vinegar, is also brought into play the effect of the excellence that the sour of its vinegar is reduced.And then, can obtain the interior oral compositions of the complete excellence of the taste of composition in its entirety, and can not damage the happy tasty and refreshing taste that acid flavoring or vinegar have.When using sweetening material, can give good sweet taste with a small amount of sweetening material in addition, thereby also as the excellent effect of oral compositions performance in the low-calorie.
Description of drawings
Fig. 1 is expression test example 2(citric acid) result's figure.
Fig. 2 is expression test example 3(citric acid) result's figure.
Fig. 3 is expression test example 5(malic acid) result's figure.
Fig. 4 is expression test example 5(tartaric acid) result's figure.
The specific embodiment
Interior oral compositions of the present invention is characterised in that, contains (A) and is selected from least a in chondroitin, chondroitin sulfate and their salt and (B) is selected from least a in acid flavoring and the vinegar, and (A) weight average molecular weight of composition is 1000～15000Da.Should illustrate that " interior oral compositions " of the present invention then is not particularly limited as long as refer to the composition that can take orally.Specifically be specified in down.
＜(A) composition＞
Employedly among the present invention be selected from least a in chondroitin, chondroitin sulfate and their salt so long as any one the material that contains in chondroitin, chondroitin sulfate and their salt then is not particularly limited, but be preferably the material that can be used for interior oral compositions.
Chondroitin sulfate refers to a kind of glycosaminoglycan that the condensation product by GalNAc and GlcUA identical with chondroitin consists of, and the part of its structure is replaced by sulfate.For example, chondroitin sulfate can be enumerated chondroitin sulfate A (CSA) (chondroitin-4-suleate), chondroitin sulfate B (dermatan sulfate), chondroitin sulfate C (6-chondroitin sulfate), chondroitin sulfate D, chondroitin sulfate E, chondroitin sulfate K etc.Wherein, preferred chondroitin, chondroitin sulfate A (CSA), chondroitin sulfate C, chondroitin sulfate D and chondroitin sulfate E, more preferably chondroitin sulfate A (CSA), chondroitin sulfate C, chondroitin sulfate D.
Chondroitin and chondroitin sulfate can use by the cartilage of animal (such as: the cartilage of horse, ox, pig, chicken, eel, shark, sturgeon, trout, carp, cod, salmon, inkfish etc.) or the natural product extraction purifying such as collagen and purifying product, illustration has the purifying product by acquisitions such as Shark cartilage, salmon cartilages.In addition, not only purifying and product, can also use the animal that will contain chondroitin or chondroitin sulfate cartilage powder and product or composite.Among them, from security and absorbefacient aspect, preferred sublimed chondroitin sulfate.Chondroitin and chondroitin sulfate can be obtained by commercially available product, perhaps can be according to known method manufacturing.
As " (A) salt of chondroitin and chondroitin sulfate " among the present invention, so long as on the pharmacology of chondroitin and chondroitin sulfate on (in the pharmacy) or the physiology acceptable arbitrarily salt get final product.As acceptable salt on the pharmacology or on the physiology, can illustration such as: acylate, inorganic acid salt (such as hydrochloride, sulfate, nitrate, hydrobromate, phosphate etc.), with the salt of organic base (such as with the salt of the organic amines such as methyl amine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidines, three pyridines, picoline etc.), with the salt of inorganic base (ammonium salt for example; With salt of the metals such as alkali metal (sodium, potassium etc.), alkaline-earth metal (calcium, magnesium etc.), aluminium etc.) etc.The sodium salt of preferably sulfuric acid chondroitin.
The salt of chondroitin and chondroitin sulfate can use according to the synthetic product that obtains of known method, also can use commercially available product.For example can enumerate: the sodium chondroitin sulfate of putting down in writing in the sodium chondroitin sulfate of record in the sodium chondroitin sulfate of record, the medicine additive specification 2003 in the outer drug specifications 2002 of Pharmacopeia of Japan, the 8th edition food additives official compendium.
Chondroitin, chondroitin sulfate and their salt can use separately, perhaps any combination more than 2 kinds are used.Wherein, the preferred use is selected from least a in chondroitin, chondroitin sulfate A (CSA), chondroitin sulfate C, chondroitin sulfate D, chondroitin sulfate E, chondroitin sulfate K and their salt, more preferably uses Chondroitine Sulfate A, SODIUM CHONDROITIN 6-SULFATE and chondroitin sulfate D sodium.(A) total content of the Chondroitine Sulfate A in the composition, SODIUM CHONDROITIN 6-SULFATE and chondroitin sulfate D sodium is preferably 10 weight (W/W) more than the %, more preferably more than the 20W/W%, more preferably more than the 50W/W%.
The weight average molecular weight of used chondroitin, chondroitin sulfate and their salt is 1000～15000Da among the present invention, but be preferably more than the 1500Da, more preferably more than the 2000Da, more preferably more than the 3000Da, more preferably more than the 5000Da, be preferably below the 15000Da.In addition, be preferably 1500～15000Da, more preferably 2000～15000Da, more preferably 3000～15000Da, more preferably 5000～15000Da.Usually, being present in the interior chondroitin of organism or the weight average molecular weight of chondroitin sulfate is about 30000～50000Da, thereby used chondroitin, chondroitin sulfate and their salt is low-molecular-weight material among the present invention.Should illustrate that in this specification, (A) weight average molecular weight of composition is obtained by the static light scattering method, particularly, can measure by the method for putting down in writing among the aftermentioned embodiment.In addition, when (A) composition comprised multiple compounds, the weight average molecular weight of contained (A) composition integral body was preferably in the above-mentioned scope in the interior oral compositions.
As the method for the chondroitin, chondroitin sulfate and their salt that obtain aforementioned molecular weight, so long as known method can adopt and be not particularly limited in the past.For example can enumerate: the alkali treatment method that chondroitin, chondroitin sulfate or their salt are decomposed, extract with alkali lye; The neutral salt facture of from chondroitin, chondroitin sulfate or their salt, extracting with neutral saline solution; Make the protein decomposition enzyme effects such as chondroitin, chondroitin sulfate or their salt and protease, pronase, the enzyme facture of decomposing, extracting; Or with their the combination method.Among them, from the high reason of the rate of recovery of low-molecular-weight chondroitin, chondroitin sulfate and their salt, preferred bases facture and enzyme facture, more preferably enzyme facture.In addition, the salt of low-molecular-weight chondroitin and chondroitin sulfate also can be to make products therefrom form salt after the low-molecular-weight in advance chondroitin and chondroitin sulfate again.Should illustrate that when chondroitin, chondroitin sulfate and their salt had substituting group, when carrying out low-molecular-weight, substituent position, its ratio did not change in fact.
Should illustrate that the treatment fluid (extract) that contains chondroitin, chondroitin sulfate and their salt that obtains by preceding method can carry out removing of insoluble matter by centrifugation, filtration etc., and then also can use as required filtration adjuvant.In addition, by with respect to the extract of removing that has carried out insoluble matter, use the active carbon about 2.5 % by weight to carry out charcoal treatment etc., also can carry out the removing of muddy composition, deodorizing, decolouring, degreasing etc.And then, can also be cured for the time being powdered by methods such as spray-drying (spray dry), evaporation drying, freeze dryings.
Be selected from least a content in chondroitin, chondroitin sulfate and their salt in the interior oral compositions of the present invention, when interior oral compositions is solid pharmaceutical preparation, be preferably more than the 1W/W%, more preferably more than the 5W/W%, more preferably more than the 10W/W%, also be preferably below the 90W/W% in addition.In addition, be preferably 1～90W/W%, more preferably 5～90W/W%, more preferably 10～90W/W%.In addition, when interior oral compositions is liquor or semisolid preparation, be preferably more than the 0.01W/W%, more preferably more than the 0.1W/W%, more preferably more than the 1W/W%, also be preferably below the 20W/W% in addition.In addition, be preferably 0.01～20W/W%, more preferably 0.1～20W/W%, more preferably 1～20W/W%.Should illustrate that " being selected from least a content in chondroitin, chondroitin sulfate and their salt " refers to the content of (A) composition of containing in the interior oral compositions of the present invention, when being multiple, then mean total content at (A) composition.In addition, (A) composition in its leaching process sometimes with contain aftermentioned (B) composition, namely, the form of acid flavoring (for example citric acid) is extracted, and therefore meant in this case to remove the content of the residual components of (B) composition.
＜(B) composition＞
Usedly among the present invention be selected from least a in acid flavoring and the vinegar so long as can be used for acid flavoring and the vinegar of interior oral compositions, then be not particularly limited.
As the acid flavoring among the present invention, with regard to concrete example, for example can enumerate: citric acid, gluconic acid, malic acid, tartaric acid, fumaric acid, lactic acid, acetic acid, adipic acid, butanedioic acid, phosphoric acid and their salt.Wherein, optimization citric acid, malic acid, tartaric acid, lactic acid, acetic acid, adipic acid, phosphoric acid, gluconic acid.
As the citric acid among the present invention and its salt, for example can enumerate: citric acid, monobasic potassium citrate, citric acid tri potassium, calcium citrate, the trisodium citrate put down in writing in the 16th calcium citrate of revising record in the citric anhydride put down in writing in the Pharmacopeia of Japan, citric acid water compound, natrium citricum hydrate, the medicine additive specification 2003, the 8th edition food additives official compendium.
As the gluconic acid among the present invention and its salt, for example can enumerate: gluconic acid, K-IAO, the gluconic acid sodium salt put down in writing in the 16th gluconic acid of revising record in the gluconic acid hydrate of calcium put down in writing in the Pharmacopeia of Japan, the medicine additive specification 2003, the 8th edition food additives official compendium.
As the malic acid among the present invention and its salt, for example can enumerate: DL-malic acid, the DL-natrium malicum put down in writing in the DL-malic acid of record in the medicine additive specification 2003, DL-natrium malicum, the 8th edition food additives official compendium.
As the tartaric acid among the present invention and its salt, for example can enumerate: the DL-tartaric acid of putting down in writing in the DL-sodium tartrate of record in the 16th potassium hydrogen tartrate of revising record in the outer drug specifications 2002 of tartaric acid, Pharmacopeia of Japan of putting down in writing in the Pharmacopeia of Japan, the medicine additive specification 2003, L-TARTARIC ACID sodium, potassium sodium tartrate, the 8th edition food additives official compendium, L-TARTARIC ACID, DL-potassium hydrogen tartrate, L-TARTARIC ACID hydrogen potassium, DL-sodium tartrate, L-TARTARIC ACID sodium, as the D-tartaric acid of CasNo.147-71-7.
As the fumaric acid among the present invention and its salt, for example can enumerate: fumaric acid, fumaric acid one sodium put down in writing in fumaric acid one sodium of record in the fumaric acid of record, the outer drug specifications 2002 of Pharmacopeia of Japan in the medicine additive specification 2003, the 8th edition food additives official compendium.
As the lactic acid among the present invention and its salt, for example can enumerate: lactic acid, calcium lactate, the sodium lactate put down in writing in the 16th aluctyl of revising record in the outer drug specifications 2002 of lactic acid, Pfansteihl, calcium lactate hydrate, Pfansteihl sodium liquid, Pharmacopeia of Japan of putting down in writing in the Pharmacopeia of Japan, the 8th edition food additives official compendium.
As the acetic acid among the present invention and its salt, for example can enumerate: the acetic acid of putting down in writing in the 16th calcium acetate of revising record in the outer drug specifications 2002 of acetic acid, glacial acetic acid, Pharmacopeia of Japan of putting down in writing in the Pharmacopeia of Japan, the 8th edition food additives official compendium.
As the adipic acid among the present invention and its salt, for example can enumerate: the adipic acid of putting down in writing in the adipic acid of record in the medicine additive specification 2003, the 8th edition food additives official compendium.
As the butanedioic acid among the present invention and its salt, for example can enumerate: butanedioic acid, butanedioic acid one sodium, the disodium succinate put down in writing in the butanedioic acid of record in the medicine additive specification 2003, butanedioic acid one sodium, disodium succinate hexahydrate, the 8th edition food additives official compendium.
As the phosphoric acid among the present invention and its salt, for example can enumerate: phosphoric acid, tripotassium phosphate, tricalcium phosphate, tricresyl phosphate magnesium, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, calcium monohydrogenphosphate, calcium dihydrogen phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, the tertiary sodium phosphate put down in writing in the phosphoric acid of record in the 16th dikalium phosphate of revising record in the outer drug specifications 2002 of dibastic sodium phosphate hydrate, biphosphate hydrate of calcium, Pharmacopeia of Japan of putting down in writing in the Pharmacopeia of Japan, potassium dihydrogen phosphate, the medicine additive specification 2003, tertiary sodium phosphate, the 8th edition food additives official compendium.
As the vinegar among the present invention, can for example enumerate and make vinegar, specifically can enumerate: rice vinegar, Oryza glutinosa vinegar, grain vinegar, Chinese sorghum vinegar, Semen setariae vinegar (grain jealous woman), apple vinegar, fruit vinegar, malt vinegar, wine vinegar, preserved plum vinegar, black vinegar, sake cake vinegar.
Be selected from least a content in acid flavoring and the vinegar in the interior oral compositions of the present invention, when interior oral compositions is solid pharmaceutical preparation, be preferably more than the 0.01W/W%, also be preferably below the 91W/W% in addition, more preferably below the 45W/W%, more preferably below the 30W/W%.In addition, be preferably 0.01～91W/W%, more preferably 0.01～45W/W%, more preferably 0.01～30W/W%.In addition, when interior oral compositions is liquor or semisolid preparation, be preferably more than the 0.01W/W%, also be preferably in addition below the 50W/W%, more preferably below the 35W/W%, more preferably below the 20W/W%.In addition, be preferably 0.01～50W/W%, more preferably 0.01～35W/W%, more preferably 0.01～20W/W%.Should illustrate, " be selected from least a content in acid flavoring and the vinegar " and refer to the content of (B) composition contained in the interior oral compositions of the present invention, at (B) composition when being multiple, mean total content, when (A) containing acid flavoring in the composition, also comprise its content and form the content of (B) composition.
In addition, (B) content of composition contain proportional, with respect to content 1 weight portion of (A) composition, be preferably more than 0.027 weight portion, be preferably below 10 weight portions, more preferably below 1 weight portion, more preferably below 0.5 weight portion, further be preferably below 0.1 weight portion.In addition, be preferably 0.027～10 weight portion, 0.027～1 weight portion more preferably, more preferably 0.027～0.5 weight portion further is preferably 0.027～0.1 weight portion.
Interior oral compositions of the present invention as long as fully realize effect of the present invention, then except (A) composition with (B) the composition, can also contain as required other various compositions (physiologically active ingredient), or they are used in combination.Kind or the amount of this composition are not particularly limited, but illustration for example: antipyretic-antalgic composition, anti-inflammatory composition, antiacid composition, crude drug composition, amino acid, inorganic salts, caffeine class, vitamins.But concrete illustration is composition as described below for example.
Antipyretic-antalgic composition: salicyclic acid derivatives (such as aspirin, aluminium aspirin, ethenzamide, disalicylic acid, salicylamide, sodium salicylate, gaultherolin, phenyl salicytate), acetyl-amino phenol, isopropylantipyrine, phenylbutazone, Indomethacin, mefenamic acid, phenaetin, C14H10Cl2NNaO2, lactyl phenetidine etc.
Anti-inflammatory composition: acceptable salt on Indomethacin, Diclofenac, piroxicam, EACA, jamaicin, glycyrrhizic acid, lysozyme, allantoin, azulenes, bromelain, serrapeptass, semialkaline protease and the pharmacology (such as berberine chloride, berberine sulfate, C14H10Cl2NNaO2, dipotassium glycyrrhizinate, ammonium glycyrrhetate, lysozyme chloride) etc.
Antiacid composition: Aluminium Hydroxide, the silicic acid magnesium aluminate, the metasilicic acid magnesium aluminate, alumina silicate, hydrotalcite, aluminum magnesium hydroxide (water acidifying ア Le ミ Na マ グ ネ シ ウ system), gel aluminum hydroxide, the coprecipitated product of aluminium hydroxide sodium acid carbonate, aluminium hydroxide magnesium carbonate combination drying gel, the coprecipitated product of aluminium hydroxide calcium carbonate magnesium carbonate, magnesium carbonate, magnesia, magnesium hydroxide, magnesium silicate, the magnesium such as coprecipitated product of magnesium hydroxide alum are antiacid, the calcium such as winnofil and calcium hydroxide is antiacid, the sodium such as sodium acid carbonate are antiacid, the anion exchange resin such as poly-aminomethylene resin, famotidine, the bisfentidine such as ranitidine and Cimetidine, proton pump inhibitor, and gastric mucin, cuttle bone, the shell of seaear, oyster, hyoscyamus extract etc.
Crude drug composition: processing garlic, carrot, coix seed, camomile, cassia bark, Gegen Decoction, Chinese ephedra, Common Nandina, cherry skin, polygala root, Radix Glycyrrhizae, almond, plantain seed, Asiatic plantain, short-tube lycoris, seneca-snakeroot, ipecac, the bulb of fritillary, gambir, fennel, the root of large-flowered skullcap, melon Lv Ren, cow-bezoar, the fruit of Chinese magnoliavine, the root of Chinese wild ginger, aster, Moschus, the root of straight ladybell, ginger, the root bark of white mulberry, Su Ye, panax japonicus, dried orange peel, ginseng, the tuber of dwarf lilyturf, the tuber of pinellia etc.
Amino acid: leucine, isoleucine, valine, methionine, threonine, alanine, phenylalanine, tryptophan, lysine, asparagine, aspartic acid, serine, glutamine, glutamic acid, proline, tyrosine, cysteine, histidine, ornithine, hydroxy-proline, oxylysine, tarine and their pharmaceutically acceptable salt (such as sparagin equal amount of mixture, cysteine hydrochloride) etc.
Inorganic salts: calcium glycerophosphate, winnofil etc.
Caffeine class: caffeine, Caffeine Anhydrous, theophylline, choline theophyllinate, dihydroxypropyltheophylline, diisobutyl aminobenzoic acyl-oxygen base propyl group theophylline, theobromine, diprophylline, brontyl, PTX etc.
Vitamins: as the retinene of retinoid, retinol, retinoic acid, carrotene, dehydroretinal, (the acetic acid retinol ester for example of acceptable salt on lycopene and its pharmacology, retinol palmitate) etc., thiamine as vitamin(e) B group, TATD, ground match thiamines, neuvitan, commetamin, vitaberin, Beprocin, prosultiamine, benfotiamine, thiamine tetrahydrofuryl disfulfide, riboflavin, flavin adenine dinucleotide (FAD), pyridoxol, pyridoxal, hydroxocobalamine, cyanocobalamin, methyl cobalamin, deoxyadenosyl cobalamin, folic acid, tetrahydrofolic acid, dihydrofoilic acid, nicotinic acid, niacinamide, nicotinic alcohol, pantothenic acid, panthenol, biotin, choline, acceptable their salt (thiamine hydrochloride for example on inositol or its pharmacology, thiamine mononitrate, hydrochloric acid ground plug thiamine, TTFD hydrochloride, Riboflavin butyrate, Riboflavin Sodium Phosphate, Flavin Adenin Dinucleotide Sodium, puridoxine hydrochloride, phosphopyridoxal pyridoxal phosphate, phosphopyridoxal pyridoxal phosphate calcium, the hydrochloric acid hydroxocobalamine, the Hydroxocobalamine Acetate element, calcium pantothenate, sodium pantothenate) etc., ascorbic acid as vitamin c class, arabo-ascorbic acid, (the sodium ascorbate for example of acceptable salt on its derivative or its pharmacology, sodium isoascorbate) etc., calciferol as the vitamin D class, cholecalciferol, hydroxycholecalciferol, the dihydroxy cholecalciferol, acceptable salt etc. on dihydrotachysterol and its pharmacology, tocopherol and its derivative as the vitamin E class, (the D-α-tocopherol acetate for example of acceptable salt on ubiquinone derivative and its pharmacology, the nicotinic acid tocopherol, the butanedioic acid tocopherol, butanedioic acid tocopherol calcium) etc., aurantiamarin as other vitamins, carnitine, forulic acid, gamma oryzanol, orotic acid, rutin sophorin, acceptable salt (such as the chlorination carnitine) etc. on eriocitrin and its pharmacology.
Interior oral compositions of the present invention as long as fully realize effect of the present invention, then also can contain common employed additive in the interior oral compositions.As additive, for example can enumerate: excipient, adhesive, disintegrant, lubricant, sweetener, flavouring, anticorrisive agent, chelating agent, antioxidant, clear Coolization agent, coating agent, stabilization agent, flowing agent, adhesion agent, dissolution aids, tackifier, buffer, spices, colouring agent, adsorbent, wetting agent, damp proof compound, antistatic agent, plasticizer, defoamer, surfactant, reinforcing agent.Specifically can enumerate such as sweetener flavourings such as Sucralose, acesulfame potassium, stevia rebaudianum, erythrite, glucose, fructose, compound sugar, xylitol, refined sugar, lactose, white sugar, mannitols; The lubricants such as dolomol, calcium stearate, sucrose fatty ester.Use Sucralose, acesulfame potassium, when erythrite is used as the sweetener flavouring, suit as oral compositions in the low-calorie.Should illustrate that the content of these compositions is not particularly limited, can at random set.
So as the specific embodiment of interior oral compositions of the present invention, can enumerate following instance.
Interior oral compositions, it contains: (A) chondroitin sulfate 0.02～10W/W%, (B) citric acid or malic acid or acetic acid amount to 0.02～5W/W%, contain in addition fructose glucose, erythrite, Sucralose, pectin, spices, colouring matter.
Interior oral compositions, it contains: (A) chondroitin sulfate 1～15W/W%, (B) citric acid or malic acid 0.5～7W/W%, contain refined sugar, fructose, Sucralose, vegetable fat, colouring agent, spices, vitamin in addition.
Interior oral compositions, it contains: (A) chondroitin sulfate 1～5W/W%, (B) citric acid or malic acid or phosphoric acid amount to 15～25W/W%, contain in addition gelating agent, Sucralose, fruit juice, spices.
Interior oral compositions, it contains: (A) chondroitin sulfate 20～60W/W%, (B) citric acid or malic acid 0.5～1.5W/W%, contain hydroxypropyl cellulose, mannitol, avicel cellulose, spices, colouring matter in addition.
As long as interior oral compositions of the present invention contain (A) composition and (B) composition then be not particularly limited, can prepare according to the method for well known to a person skilled in the art.
Particularly, when interior oral compositions of the present invention is solid composite, for example can enumerate: to contain (A) composition, (B) composition, as required other physiologically active ingredient and the raw material of the solid composite of additive mix, the mixture that obtains is thus directly dropped into the method (direct compression process) that tablet press machine carries out processing and forming.In addition, also can carry out granulation (for example extruding pelletization, fluidized bed prilling or the granulation of spray-drying formula) according to known method, then drop into tablet press machine and carry out processing and forming.Should illustrate, shape, the size of this solid composite is not particularly limited, can carry out according to known method the Cotton seeds such as sugar-coat or film dressing.
When interior oral compositions of the present invention is liquor or gel, for example, can with contain (A) composition, (B) composition, as required other physiologically active ingredient and the raw material of the liquor of additive with after an amount of pure water dissolving or disperseing, regulate pH(25 ℃) to preferred 2～8, more preferably 2.5～7, further preferred 3～6, then, for the situation of liquor, add remaining pure water and carry out capacity regulating, cool off as required, make thus.Here, preferred employing is with aforementioned (A) composition and (B) the well-mixed method of composition.Interior oral compositions of the present invention (liquor or gel) also can filter and sterilization treatment as required, and is filled in the container.Should illustrate, capacity, the viscosity of this liquor or gel is not particularly limited, can the processing such as dilute, concentrate according to known method.In addition, when being made as when using the liquor that the raw mix dissolving of aforementioned liquor or gel formed aqueous time spent blending type or gel, can also be with the known liquid dissolving such as drinking water, milk, disperse use.
The container that is used for carrying out filling can use this areas such as raw materials for plastics production, glass raw material and raw material metal to can be used for the raw material of common container, and they can be according to purpose, the purposes choice for use that suits.
When interior oral compositions of the present invention was liquor or gel, the content of the water in the interior oral compositions of the present invention was preferably more than the 10W/V%, more preferably more than the 15W/V%, also was preferably in addition below the 99.8W/V%, more preferably below the 99.5W/V%.In addition, be preferably 10～99.8W/V%, more preferably 15～99.5W/V%.
When interior oral compositions of the present invention is liquor or gel, the pH(25 of interior oral compositions ℃) be preferably more than 2, more preferably more than 2.5, more preferably more than 3, also be preferably in addition below 8, more preferably below 7, more preferably below 6.In addition, be preferably 2～8, more preferably 2.5～7, more preferably 3～6.
When interior oral compositions of the present invention is liquor or gel, viscosity during 25 ℃ of interior oral compositions, (RE550 type viscosimeter, eastern machine industry company make, rotor: 1 ° of 34 ' * R24) measurement for example to use rotation viscometer, be preferably more than the 0.01mPa s, more preferably more than the 0.05mPa s, more preferably more than the 0.1mPa s, also be preferably in addition below the 1000mPa s, more preferably below the 100mPa s, more preferably below the 10mPa s.In addition, be preferably 0.01～1000mPa s, more preferably 0.05～100mPa s, more preferably 0.1～10mPa s.
When interior oral compositions of the present invention is liquor or gel, not only can be the manner of packing of only taking for 1 time, can also pack and the interior oral compositions of the multiple dose that can use continuously as the user also is useful in the mode of repeatedly taking.
When interior oral compositions of the present invention is semisolid preparation, for example, can in (A) composition, mix and contain (B) composition, the raw material of the semisolid preparation of his physiologically active ingredient of as required other and additive, the mixture that obtains thus is direct with an amount of dissolution with solvents or after disperseing, regulate pH(25 ℃) to preferred more than 2, more preferably more than 2.5, further preferred more than 3, preferred below 8, more preferably below 7, further preferred below 6, preferred 2～8 in addition, more preferably 2.5～7, further preferred 3～6, then, add remaining solvent and carry out capacity regulating, make thus.Here, preferred employing is with aforementioned (A) composition and (B) the well-mixed method of composition.
Interior oral compositions of the present invention comprises and can be widely used in such as the arbitrarily preparation in medicine, quasi drug, the food etc. (for example, pharmaceutical preparation, quasi drug preparation or specific food for health care, trophic function food, old man with the food preparations such as food, special purposes food, functional food, healthy accesary foods (fill-in) or cake tablet processed (System Fruit Ingot drug)).
Interior oral compositions of the present invention can use as form for oral administration according to purpose.As its preparation form, be limited taking orally, be not particularly limited.Concrete example is shown with: powder, powder agent, granula subtilis, granule, pill, capsule, tablet (but comprising plain sheet, sugar coated tablet, oral quick disintegrating tablet chewable tablets (chewable tablets), foamed sheet, lozenge, film coating tablet etc.), dry syrup, film, liquor (comprising supensoid agent, emulsion, syrup, limonada etc.), gel also comprise cake agent processed (candy (sugar), adhesive (グ ミ drug), nougat agent etc.).
Interior oral compositions of the present invention can use according to its preparation form and be not particularly limited.In addition, can also be aptly be used for such as expecting that effect by (A) composition realizes that the disease of effect and daily health promotes or keep etc.Can be used for improvement and/or prevention such as the symptom of chronic nephritis, neuralgia, arthralgia, lumbago diseases, scapulohumeral periarthritis (frozen shoulder) etc.In addition, can also be used for the improvement etc. of the inhibition of wrinkle and/or prevention, skin condition.
As the object that gives of interior oral compositions of the present invention, preferably can enumerate the people of the effect that need to improve chronic nephritis, neuralgia, arthralgia, lumbago diseases, scapulohumeral periarthritis (frozen shoulder), wrinkle, skin condition.In addition, interior oral compositions of the present invention is safe composition, thereby also can be with the patient of concurrent Other diseases or normal healthy people for giving object, and then can also give animals such as pet etc.
The amount that the administered dose of interior oral compositions of the present invention so long as can obtain embodies the desired effect of the present invention gets final product, can be according to its form, give method, the age that gives object, body weight, the symptom that give purpose and said composition suit to set, and be and non-constant.For example, with respect to each adult, (A) composition is that 100～400mg/ time amount can be enumerated and is preferred administered dose.In addition, in desired administered dose scope, but in 1 day single or give several times, also be arbitrarily during giving.Should illustrate that " the giving " in this specification means the implication of " giving " and/or " picked-up ".
Even interior oral compositions of the present invention contain be selected from least a in acid flavoring and the vinegar in, also bring into play the repressed effect of sour of vinegar.So the present invention also provides the method that makes the sour reduction that contains the vinegar that is selected from least a interior oral compositions in acid flavoring and the vinegar.
The method that reduces as the sour of the vinegar that makes interior oral compositions, concrete be selected from least a in acid flavoring and the vinegar so long as in interior oral compositions, contain (B), also contain simultaneously (A) and be selected from least a in chondroitin, chondroitin sulfate and their salt, and the weight average molecular weight of aforementioned (A) composition is 1000～15000Da, then is not particularly limited.
Should illustrate that in the method that the sour of the vinegar that makes aforementioned interior oral compositions reduces, (A) composition can carry out simultaneously with cooperating of (B) composition, also can carry out respectively that it sequentially also is not particularly limited.In addition, in the said method, for (A) composition that uses and (B) kind, their content of composition and they contain proportional and to add the composition of cooperation kind, preparation method, purposes, preparation form, give object etc., identical with aforementioned interior oral compositions of the present invention.
Embodiment
Below, the present invention will be described based on embodiment, but the present invention is not subjected to any restriction of these embodiment etc.Should illustrate, chondroitin sulfate in each test example be the purifying Shark cartilage and commercially available product, the about 30000Da of weight average molecular weight of specification that will be suitable for the sodium chondroitin sulfate of medicine additive specification 2003, decompose by the enzyme facture of having used catabolic enzyme, extract the material with each weight average molecular weight and use.In addition, the sodium chondroitin sulfate before decomposing and the sodium chondroitin sulfate that has decomposed contain citric acid 2.63% separately, thereby have considered this situation and adjust, forming content of record in each table.The unit of the component content in each table is " mg ".
(weight average molecular weight of chondroitin, chondroitin sulfate and their salt)
The weight average molecular weight of chondroitin, chondroitin sulfate and their salt can be measured by the static light scattering method.Particularly, use dynamic light scattering photometer (DLS-8000(Otsuka Electronics Co., Ltd.)), utilize following condition to carry out.Sample is dissolved in the pure water, is prepared, so that concentration is 10mg/mL.This solution further with pure water dilution, is prepared, so that concentration is 2,4,6,8mg/mL.Carry out the static light scattering mensuration of 20,30,40,60,90,120,150 ° angle under 25 ℃ and the dn/dc of intrinsic index increment and measure, by Zimm square root curve (プ ロ ッ ト) and Debye curve calculation weight average molecular weight.Should illustrate that the filter with aperture 0.22 μ m before diffuse transmission measuring carries out the filtration of sample.Dn/dc measure can the manufacturing of Yong Da mound electronics DRM-3000 measure.
Test example 1
Comparative example 1～2 shown in the preparation table 1 and the interior oral compositions of embodiment 1 use oral compositions in these respectively, and (Visual Analogue Scale, VAS) carries out the evaluation of the sour of vinegar according to visual analogue scales.Should illustrate, the following selection of syndic, that is, from the composition for comparative example 1, the scoring of estimating the sour of aftermentioned vinegar is to select 5 people to use among 2.1～6.5 the people.
Particularly, behind each composition of record, be dissolved in the pure water of 70mL in the weighing table 1.Then, utilizing the sodium hydroxide solution of 0.1N to be adjusted to each pH, is 100mL with the pure water constant volume, obtains interior oral compositions.And then " sour of vinegar " felt for the interior oral compositions that takes gained orally, with do not feel the situation of sour of vinegar as 0cm, feel the situation of sour of vinegar as 5cm, strongly feel the situation of sour of vinegar as 10cm, the degree of the sense organ that the syndic is felt is recorded in the sense organ application form.Afterwards, measure the power of " sour of vinegar " by the sense organ application form in the mode of length (cm), this length (cm) is marked to calculate as the sour of vinegar.Use the sour scoring of each syndic's vinegar, the sour inhibiting rate by following formula (1) calculating vinegar calculates its mean value.Should illustrate, in the test example 1 with comparative example 1 in contrast.The results are shown in table 1.
The sour inhibiting rate (%) of vinegar={ (the sour scoring of the vinegar of contrast)-(the sour scoring of the vinegar of each sample) }/(the sour scoring of the vinegar of contrast) * 100 (1).
Should illustrate that citric acid meets the specification of food additives.
[table 1]
Sour for the vinegar of the interior oral compositions that contains citric acid by contain the sodium chondroitin sulfate of the about 5000Da of weight average molecular weight in interior oral compositions, confirms the inhibition (embodiment 1) of the sour of significant vinegar.With respect to this, in the interior oral compositions of the sodium chondroitin sulfate that contains citric acid and the about 30000Da of weight average molecular weight, the not only inhibition of the sour to significant vinegar unconfirmed, on the contrary the sour grow of vinegar (comparative example 2).
As can be known from the above results, by containing low-molecular-weight sodium chondroitin sulfate, can be observed the inhibition of the sour of significant vinegar.
Test example 2
The comparative example 1 shown in the preparation table 2,3 and the interior oral compositions of embodiment 2～4 respectively, with test example 1 in the same manner, for contrast, carry out the evaluation of sour of the vinegar of each interior oral compositions take comparative example 1.Should illustrate that citric acid uses the citric acid identical with test example 1.Result and embodiment 1 and comparative example 2 the results are shown in table 2 and Fig. 1.
[table 2]
In the interior oral compositions of the sodium chondroitin sulfate that contains citric acid and the about 20000～30000Da of weight average molecular weight, the sour of the vinegar of citric acid not suppressed (comparative example 2 and 3), with respect to this, in the interior oral compositions of the sodium chondroitin sulfate that contains citric acid and the about 5000～15000Da of weight average molecular weight, confirmed the inhibition of sour of the vinegar of significant citric acid.
As can be known from the above results, by containing the sodium chondroitin sulfate of citric acid and specified molecular weight, can be observed the inhibition of the sour of significant vinegar.
Test example 3
The respectively comparative example 4 shown in the preparation table 3 and the interior oral compositions of embodiment 5～8, with test example 1 in the same manner, carry out the evaluation of sour of the vinegar of interior oral compositions.Should illustrate, in test example 3, calculate the sour inhibiting rate of vinegar as contrast take comparative example 4.In addition, citric acid uses the citric acid identical with test example 1.The results are shown in table 3 and Fig. 2.
[table 3]
With respect to citric acid 100mg, contain in the interior oral compositions of sodium chondroitin sulfate 10～3700mg of weight average molecular weight about 5000, confirmed the inhibition of sour of the vinegar of significant citric acid.
Test example 4
The respectively comparative example 5～14 shown in the preparation table 4～6 and the interior oral compositions of embodiment 9～13, with test example 1 in the same manner, carry out the evaluation of sour of the vinegar of interior oral compositions.Should illustrate, embodiment 9 and comparative example 6 are take comparative example 5 as contrast, embodiment 10 and comparative example 8 are take comparative example 7 as contrast, embodiment 11 and comparative example 10 are take comparative example 9 as contrast, embodiment 12 and comparative example 12 are take comparative example 11 as contrast, embodiment 13 and comparative example 14 calculate respectively the sour inhibiting rate of vinegar take comparative example 13 as contrast.In addition, for the syndic, select for the acid flavoring of each cooperation, the sour of each comfortable comparative example 5,7,9,11 or 13 vinegar is evaluated as among 2.1～8.0 the people selection 3 people as the syndic.The results are shown in table 4～6.
Should illustrate that phosphoric acid, lactic acid and gluconic acid meet the specification of food additives, malic acid meets the specification of the DL-malic acid of food additives, and tartaric acid meets the tartaric specification of DL-of food additives.
[table 4]
[table 5]
[table 6]
When the citric acid that uses in embodiment 1 replaces with in malic acid, tartaric acid, phosphoric acid, lactic acid and the gluconic acid any one, in the interior oral compositions of the sodium chondroitin sulfate that contains acid flavoring and the about 5000Da of weight average molecular weight, also observed the remarkable inhibition of the sour of vinegar, with respect to this, in the interior oral compositions of the sodium chondroitin sulfate that contains acid flavoring and the about 30000Da of weight average molecular weight, the sour of vinegar significantly increases (comparative example 5～14 and embodiment 9～13).
By these results as can be known, by containing low-molecular-weight sodium chondroitin sulfate, can be observed the remarkable inhibition of sour of the vinegar of various acid flavorings.
Test example 5
The respectively comparative example 15～16 shown in the preparation table 7 and 8 and the interior oral compositions of embodiment 14～23, with test example 1 in the same manner, carry out the evaluation of sour of the vinegar of interior oral compositions.Should illustrate, embodiment 14～18 with comparative example 15 in contrast, embodiment 19～23 calculates the sour inhibiting rate of vinegar with comparative example 16 in contrast.In addition, for the syndic, select for the acid flavoring of each cooperation, the sour of each comfortable comparative example 15 or 16 vinegar is evaluated as among 2.1～8.0 the syndic selection 3 people as the syndic.The results are shown in table 7～8 and Fig. 3～4.
Should illustrate that malic acid and tartaric acid use malic acid and the tartaric acid identical with test example 4.
[table 7]
[table 8]
With respect to malic acid or tartaric acid 100mg, contain in the interior oral compositions of sodium chondroitin sulfate 1～1205mg of the about 5000Da of weight average molecular weight, confirmed the inhibition of the sour of significant malic acid or tartaric vinegar.
Test example 6
The respectively comparative example 17～18 shown in the preparation table 9 and the interior oral compositions of embodiment 24, with test example 1 in the same manner, carry out the evaluation of sour of the vinegar of interior oral compositions.Should illustrate, in test example 6, calculate the sour inhibiting rate of vinegar as contrast take comparative example 17.In addition, for the syndic, from being 2.1～8.0 people, the sour scoring of the vinegar of evaluation comparison example 17 select 3 people as the syndic.Rice vinegar meets the JAS specification.
[table 9]
When the citric acid that uses in embodiment 1 replaces with rice vinegar, in the interior oral compositions of the sodium chondroitin sulfate that contains the about 5000Da of weight average molecular weight, also observed the remarkable inhibition of the sour of vinegar, with respect to this, in the interior oral compositions of the sodium chondroitin sulfate that contains the about 30000Da of weight average molecular weight, the sour of vinegar significantly increases (comparative example 17～18 and embodiment 24).
By these results as can be known, by containing low-molecular-weight sodium chondroitin sulfate, can be observed the remarkable inhibition of the sour of the vinegar in the vinegar.
Test example 7
With the Formulation Example of the embodiment 25～28 shown in the table 10, with embodiment 1 be 100mL with the pure water constant volume in the same manner, the preparation reduced calorie beverage.For above-mentioned beverage, carry out the sensory evaluation of tart flavour and sweet taste by the syndic identical with test example 4.
[table 10]
As a result, for these reduced calorie beverage, confirmed the remarkable inhibition of the sour of vinegar, and then the too dense sweet taste or the not good aftertaste that do not have sweetening material to have, given good sweet taste.
Below enumerate Formulation Example.
Formulation Example: liquor
Chondroitin sulfate 200mg
Hyaluronic acid 60mg
Collagen peptide 500mg
Soybean polysaccharides 180mg
Pectin 180mg
Erythrite 3000mg
Sucralose 5mg
Acesulfame potassium 3mg
Spices 150mg
Citric acid 350mg
Water is an amount of
Amount to 50g.
Formulation Example: gel
Chondroitin sulfate 300mg
Erythrite 8000mg
Sucralose 45mg
Spices 900mg
Gelating agent 1300mg
Citric acid 1200mg
Citric acid Na 500mg
Water is an amount of
Amount to 10g.
Formulation Example: whitening beverage
Chondroitin sulfate 100mg
Hyaluronic acid 60mg
Collagen peptide 3000mg
Yeast extract 100mg
Agar 100mg
Pectin 90mg
Fructose Glucose Liquid sugar 1300mg
Honey 500mg
Stevia rebaudianum 5mg
Spices 120mg
Malic acid 380mg
Water is an amount of
Amount to 50g.
Formulation Example: dispelling cold beverage (cold え solution disappear De リ Application Network)
Chondroitin sulfate 50mg
Glucose 2000mg
Piper longum extract 50mg
Ginger P.E 50mg
Fructus Monordicae extract 15mg
Spices 100mg
Emulsifying agent 20mg
Vitamin B1 1.5mg
Vitamin B2 1.5mg
Vitamin C 300mg
Vitamin B6 5mg
Caramel 50mg
Vinegar 700mg
Water is an amount of
Amount to 50g.
Formulation Example: soda
Granulated sugar 10000mg
Guarana extract 5mg
Soybean polysaccharides 200mg
Carrotene pigment 800mg
Caffeine 30mg
Soybean Peptide 1000mg
Placenta 500mg
Royal jelly 50mg
Bird's nest 50mg
Fruit juice 3000mg
Tartaric acid 600mg
Elastin laminin 50mg
Water is an amount of
Amount to 100g
(the pressure carbon dioxide after the filling (20 ℃) 1.3kg/cm
2).
Formulation Example: beauty-care beverage
Chondroitin sulfate 180mg
Malt sugar 1000mg
Compound sugar 300mg
Ascorbic acid 350mg
Phytic acid 250mg
Extract of soybean 100mg
Marine algae extract 50mg
Nicotinic acid 20mg
Pectin 350mg
Spices 100mg
Water is an amount of
Amount to 50g.
Formulation Example: beauty-care beverage
Chondroitin sulfate 250mg
Ellagic acid 60mg
Collagen peptide 5000mg
Cyclodextrin 100mg
Agar 100mg
Pectin 90mg
Fructose Glucose Liquid sugar 1300mg
Vitamin E 5mg
Refined sugar 2000mg
Spices 100mg
Malic acid 380mg
L-AA Na 30mg
Water is an amount of
Amount to 50g.
Formulation Example: beauty-care beverage
Chondroitin sulfate 100mg
Citric acid 60mg
Rice extracts 50mg
Cyclodextrin 100mg
Tackify polysaccharide 100mg
Gelatin 90mg
Xylitol 1500mg
Vitamin E 5mg
Stevia rebaudianum 50mg
Spices 200mg
Catechin 20mg
Water is an amount of
Amount to 50g.
Formulation Example: masticatory
Chondroitin sulfate 150mg
Glucosamine hydrochloride 150mg
N-acetyl glucosamine 5mg
Avicel cellulose 30mg
Methylcellulose 7mg
Silica 3.5mg
Spices 3.5mg
Sucrose fatty ester 3mg
Calcium stearate 10mg
Amount to 362mg.
Formulation Example: granule
Chondroitin sulfate 200mg
Mannitol is an amount of
Avicel cellulose 20mg
Hydroxypropyl cellulose 15mg
Starch 100mg
Citric acid 70mg
Citric acid Na 10mg
Spices 5mg
Aspartame 5mg
Anhydrous lightweight silicic acid 15mg
Dolomol 50mg
Amount to 565mg.
Industrial applicability
Even interior oral compositions of the present invention when containing acid flavoring or vinegar, is also brought into play the effect of the excellence that the sour of its vinegar is reduced.Thus, when containing acid flavoring or vinegar, there are not pungent taste or the interior oral compositions of aftertaste even can provide yet.
Claims (4)
1. interior oral compositions, it contains (A) and is selected from least a in chondroitin, chondroitin sulfate and their salt and (B) is selected from least a in acid flavoring and the vinegar,
(A) weight average molecular weight of composition is 1000～15000Da.
2. interior oral compositions according to claim 1, wherein, (A) composition contains sodium chondroitin sulfate.
3. interior oral compositions according to claim 1 and 2, wherein, (B) composition contain be selected from citric acid, malic acid, tartaric acid, acetic acid, lactic acid, phosphoric acid, gluconic acid and make vinegar at least a.
4. the method that the sour of the vinegar of interior oral compositions is reduced is characterized in that, contains (B) and be selected from least a in acid flavoring and the vinegar in interior oral compositions, also contains simultaneously (A) and is selected from least a in chondroitin, chondroitin sulfate and their salt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-099988 | 2012-04-25 | ||
| JP2012099988 | 2012-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103371349A true CN103371349A (en) | 2013-10-30 |
Family
ID=49457666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101470264A Pending CN103371349A (en) | 2012-04-25 | 2013-04-25 | Orally taken composition |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP6096550B2 (en) |
| CN (1) | CN103371349A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6760710B2 (en) * | 2013-09-13 | 2020-09-23 | 大正製薬株式会社 | Beverage |
| JP6798314B2 (en) * | 2014-11-27 | 2020-12-09 | 大正製薬株式会社 | Aqueous liquid beverage |
| JP6876217B2 (en) * | 2017-05-19 | 2021-05-26 | 二村 芳弘 | Peptidoglycan derivative with anti-inflammatory effect |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3405120A (en) * | 1966-01-27 | 1968-10-08 | Green Cross Corp | Low molecular chondroitin sulfate and method for manufacturing the same |
| CN1575182A (en) * | 2001-08-14 | 2005-02-02 | 法马西亚公司 | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| CN102105154A (en) * | 2008-07-30 | 2011-06-22 | 三得利控股株式会社 | Preparation for oral administration comprising water-extracted chondroitin sulfate and quercetin glycoside |
| CN102302116A (en) * | 2011-06-10 | 2012-01-04 | 营养屋(成都)生物医药有限公司 | Calcium supplementing and calcium locking health care food and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05163154A (en) * | 1991-12-13 | 1993-06-29 | Kanebo Ltd | Peroral liquid agent |
| JP4034024B2 (en) * | 2000-02-22 | 2008-01-16 | 株式会社日本バリアフリー | Functional food |
| JP5491943B2 (en) * | 2010-04-28 | 2014-05-14 | ゼリア新薬工業株式会社 | Oral jelly containing vitamin B1 |
-
2013
- 2013-03-26 JP JP2013064570A patent/JP6096550B2/en active Active
- 2013-04-25 CN CN2013101470264A patent/CN103371349A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3405120A (en) * | 1966-01-27 | 1968-10-08 | Green Cross Corp | Low molecular chondroitin sulfate and method for manufacturing the same |
| DE1618454A1 (en) * | 1966-01-27 | 1971-03-25 | Gren Cross Corp | New chondroitin sulfate and process for its manufacture |
| CN1575182A (en) * | 2001-08-14 | 2005-02-02 | 法马西亚公司 | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| CN102105154A (en) * | 2008-07-30 | 2011-06-22 | 三得利控股株式会社 | Preparation for oral administration comprising water-extracted chondroitin sulfate and quercetin glycoside |
| CN102302116A (en) * | 2011-06-10 | 2012-01-04 | 营养屋(成都)生物医药有限公司 | Calcium supplementing and calcium locking health care food and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013241393A (en) | 2013-12-05 |
| JP6096550B2 (en) | 2017-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105077270A (en) | Nutrient supplemented composite powder as well as preparation method and use thereof | |
| CN103371349A (en) | Orally taken composition | |
| KR20090021288A (en) | Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue | |
| JPWO2014010656A1 (en) | Excellent promoter for lowering blood alcohol levels | |
| JP4674955B2 (en) | Amino sugar-containing preparation | |
| JP5961034B2 (en) | Stabilization method | |
| RU2468812C2 (en) | Agent possessing adaptogenic, tonic and general tonic action, and method for preparing it | |
| JP7460352B2 (en) | Liquid or semi-solid compositions | |
| JP2013079201A (en) | Capsule agent filled with liquid composition containing caffeines | |
| CN109380728B (en) | Composition and health food with auxiliary blood pressure lowering effect | |
| WO2021136784A1 (en) | A composition for the treatment of male infertility | |
| JP6840647B2 (en) | Liquid composition, its cloudiness improving agent, odor improving agent, and manufacturing method | |
| JP2012149060A (en) | Composition | |
| JP2007277207A (en) | Preparation for internal use | |
| JP2012153623A (en) | Bofutsushosan-containing composition | |
| JP6114133B2 (en) | Kokushi extract-containing oral solution, solubilizer and solubilization method | |
| JP2013032407A (en) | Composition for treating or preventing arthralgia | |
| KR102619728B1 (en) | Heat-stable oral disintegrating film comprising S-allyl-L-cysteine from fermented black garlic and manufacturing method thereof | |
| JP2008127371A (en) | Stable internal liquid medicine composition | |
| JP5329866B2 (en) | Pharmaceutical composition and preventive and therapeutic agent for joint disorders | |
| JP7349424B2 (en) | Composition | |
| JP2004091420A (en) | Medicinal composition for internal use | |
| WO2013129551A1 (en) | Solid composition | |
| JP2023015409A (en) | Oral gelatinous composition | |
| AU2015266075A1 (en) | Oral composition for improving systemic symptoms including sensitivity to cold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1190879 Country of ref document: HK |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20171222 |
|
| AD01 | Patent right deemed abandoned | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1190879 Country of ref document: HK |